Navellier & Associates
NEPH icon

Navellier & Associates’s Nephros NEPH Stock Holding History

Navellier & Associates’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-53,479
Closed -$191K – 325
2026
Q2 		$191K Buy
53,479
+34,353
+180% +$112K 0.02% 315
2026
Q1 		$57K Sell
19,126
-8,049
-30% -$32.1K 0.01% 326
2025
Q4 		$133K Buy
+27,175
New +$139K 0.01% 322

Other funds holding NEPH

Massachusetts Institute of Technology
Massachusetts Institute of Technology Cambridge, Massachusetts $695M AUM 43.77% 1-Year Est. Return
Wexford Capital
Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Meritage Group
Meritage Group San Francisco, California $2.78B AUM 9.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Bard Associates
Bard Associates Chicago, Illinois $431M AUM 30.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Mesirow Financial Investment Management
Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

Navellier & Associates's NEPH Position: Q3 2026 in Review

Navellier & Associates sold out of Nephros (NEPH) in Q3 2026, closing a stake of 53,479 shares — an estimated $191K sold.

Navellier & Associates first reported a position in NEPH in Q4 2025 and held it in 3 quarters. The position peaked at $191K in Q2 2026. 26 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

  • Navellier & Associates reported no remaining Nephros position as of Q3 2026 after selling out during the quarter.
  • Navellier & Associates sold 53,479 Nephros shares in Q3 2026, an estimated $191K.
  • Navellier & Associates first reported a position in Nephros in Q4 2025 and held it in 3 quarters.
  • Navellier & Associates's Nephros position peaked at $191K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on Navellier & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.